Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was the target of a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 598,943 shares, a decline of 23.2% from the August 31st total of 779,902 shares. Based on an average daily trading volume, of 178,063 shares, the short-interest ratio is currently 3.4 days. Approximately 5.2% of the company’s shares are short sold.

Several brokerages recently commented on SYRS. JMP Securities lowered shares of Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 10th. Wedbush reaffirmed an “outperform” rating and set a $22.84 price target (down previously from $25.00) on shares of Syros Pharmaceuticals in a research report on Thursday, August 10th. Cowen and Company reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, August 9th. Cann reaffirmed a “buy” rating and set a $28.00 price target on shares of Syros Pharmaceuticals in a research report on Monday, August 21st. Finally, Oppenheimer Holdings, Inc. set a $28.00 price target on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, June 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. Syros Pharmaceuticals currently has an average rating of “Buy” and an average price target of $24.64.

In other news, Director Richard A. Young sold 3,282 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $22.09, for a total value of $72,499.38. Following the completion of the transaction, the director now owns 423,383 shares of the company’s stock, valued at $9,352,530.47. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Eric R. Olson sold 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $21.85, for a total transaction of $273,125.00. Following the completion of the transaction, the insider now directly owns 12,500 shares of the company’s stock, valued at approximately $273,125. The disclosure for this sale can be found here. In the last three months, insiders sold 21,564 shares of company stock valued at $476,803.

Large investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC raised its position in shares of Syros Pharmaceuticals by 114.7% in the second quarter. ARK Investment Management LLC now owns 17,705 shares of the company’s stock valued at $285,000 after purchasing an additional 9,460 shares during the period. Wells Fargo & Company MN bought a new position in shares of Syros Pharmaceuticals in the first quarter valued at approximately $225,000. Redmile Group LLC raised its position in shares of Syros Pharmaceuticals by 0.5% in the first quarter. Redmile Group LLC now owns 952,740 shares of the company’s stock valued at $15,177,000 after purchasing an additional 4,300 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Syros Pharmaceuticals in the first quarter valued at approximately $185,000. Finally, FMR LLC raised its position in shares of Syros Pharmaceuticals by 11.9% in the second quarter. FMR LLC now owns 3,926,998 shares of the company’s stock valued at $63,185,000 after purchasing an additional 418,061 shares during the period. 59.61% of the stock is currently owned by institutional investors.

Syros Pharmaceuticals (NASDAQ SYRS) opened at 14.72 on Friday. The company’s 50-day moving average is $16.38 and its 200 day moving average is $16.38. The firm’s market cap is $386.55 million. Syros Pharmaceuticals has a 12 month low of $10.22 and a 12 month high of $17.89.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.03. On average, equities research analysts predict that Syros Pharmaceuticals will post ($2.09) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Syros Pharmaceuticals, Inc. (SYRS) Short Interest Update” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/syros-pharmaceuticals-inc-syrs-short-interest-update/1599855.html.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.